Claims
- 1. A method of preventing or inhibiting adverse cardiovascular effects associated with administration of a sympathetic nervous system antagonist in a subject, comprising administering to a subject in need thereof a sympathetic nervous system antagonist and an endothelin antagonist.
- 2. The method of claim 1, wherein the sympathetic nervous system antagonist and the endothelin antagonist are coadministered.
- 3. The method of claim 1, wherein the sympathetic nervous system antagonist and the endothelin antagonist are administered as a single dosage unit.
- 4. The method of claim 1, wherein the sympathetic nervous system antagonist is an alpha-adrenoceptor antagonist.
- 5. The method of claim 4, wherein the alpha-adrenoceptor antagonist is selected from the group consisting of doxazosin, prazosin, terazosin, and phentolamine.
- 6. The method of claim 1, wherein the sympathetic nervous system antagonist is a ganglionic blocking agent.
- 7. The method of claim 1, wherein the sympathetic nervous system antagonist is selected from the group consisting of hexamethonium, mecamylamine, clonidine, guanethidine, and reserpine.
- 8. The method of claim 1, wherein the endothelin antagonist is selected from the group consisting of ABT-627, Bosentan, SB209670, and an NO-mimetic.
- 9. A method for improving the efficacy of a sympathetic nervous system antagonist, comprising administering to a subject in need thereof a sympathetic nervous system antagonist together with an endothelin antagonist.
- 10. The method of claim 9, wherein the sympathetic nervous system antagonist and the endothelin antagonist are administered sequentially.
- 11. The method of claim 9, wherein the sympathetic nervous system antagonist and the endothelin antagonist are coadministered.
- 12. The method of claim 11, wherein the sympathetic nervous system antagonist and the endothelin antagonist are administered as a single dosage unit.
- 13. The method of claim 9, wherein the sympathetic nervous system antagonist is an alpha-adrenoceptor antagonist.
- 14. The method of claim 13, wherein the alpha-adrenoceptor antagonist is selected from the group consisting of doxazosin, prazosin, terazosin, and phentolamine.
- 15. The method of claim 9, wherein the sympathetic nervous system antagonist is a ganglionic blocking agent.
- 16. The method of claim 9, wherein the sympathetic nervous system antagonist is selected from the group consisting of hexamethonium, mecamylamine, clonidine, guanethidine, and reserpine.
- 17. The method of claim 9, wherein the endothelin antagonist is selected from the group consisting of ABT-627, Bosentan, SB209670, and an NO-mimetic.
- 18. A method of treating prostate cancer or benign prostate hyperplasia (BPH) in a subject, comprising administering to a subject in need thereof a sympathetic nervous system antagonist and an endothelin antagonist.
- 19. The method of claim 18, wherein the sympathetic nervous system antagonist and the endothelin antagonist are administered sequentially.
- 20. The method of claim 18, wherein the sympathetic nervous system antagonist and the endothelin antagonist are coadministered.
- 21. The method of claim 20, wherein the sympathetic nervous system antagonist and the endothelin antagonist are administered as a single dosage unit.
- 22. The method of claim 18, wherein the sympathetic nervous system antagonist is an alpha-adrenoceptor antagonist.
- 23. The method of claim 22, wherein the alpha-adrenoceptor antagonist is selected from the group consisting of doxazosin, prazosin, terazosin, and phentolamine.
- 24. The method of claim 18, wherein the sympathetic nervous system antagonist is a ganglionic blocking agent.
- 25. The method of claim 18, wherein the sympathetic nervous system antagonist is selected from the group consisting of hexamethonium, mecamylamine, clonidine, guanethidine, and reserpine.
- 26. The method of claim 18, wherein the endothelin antagonist is selected from the group consisting of ABT-627, Bosentan, SB209670, and an NO-mimetic.
RELATED APPLICATIONS
This application claims the benefit of priority of U.S. Provisional Patent Application No. 60/226,098, filed Aug. 18, 2000, the contents of which are incorporated herein by reference in their entirety.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5538991 |
Ashton et al. |
Jul 1996 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/226098 |
Aug 2000 |
US |